Gefitinib, as the first‐line EGFR‐TKI, provides significant clinical benefits in NSCLC patients, yet acquired resistance occurs in virtually all NSCLC tumors that initially respond to it (Gazdar, 2009). This evidence concerns the gene EGFR and non-small cell lung carcinoma.